Biomm S.A Asset Resilience Ratio
Biomm S.A asset resilience ratio. Biomm S.A (BIOM3) has an Asset Resilience Ratio of 14.65% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BIOM3 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biomm S.A (2013–2024)
Asset resilience ratio of Biomm S.A from 2013 to 2024. This chart shows how Biomm S.A's Asset Resilience Ratio has changed over time. Read how much debt does Biomm S.A carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biomm S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BIOM3 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$11.50 Million | 2.37% |
| Short-term Investments | R$59.53 Million | 12.27% |
| Total Liquid Assets | R$71.03 Million | 14.65% |
Asset Resilience Insights
- Moderate Liquidity: Biomm S.A has 14.65% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Biomm S.A Industry Peers by Asset Resilience Ratio
Compare Biomm S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Biomm S.A Asset Resilience Ratio by Year (2013–2024)
Biomm S.A asset resilience ratio by year from 2013 to 2024. The table below shows the annual Asset Resilience Ratio data for Biomm S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 29.70% | R$138.28 Million ≈ $27.13 Million |
R$465.66 Million ≈ $91.37 Million |
+14.47pp |
| 2023-12-31 | 15.22% | R$52.47 Million ≈ $10.29 Million |
R$344.70 Million ≈ $67.64 Million |
-9.16pp |
| 2022-12-31 | 24.38% | R$98.78 Million ≈ $19.38 Million |
R$405.09 Million ≈ $79.49 Million |
+9.69pp |
| 2021-12-31 | 14.69% | R$54.34 Million ≈ $10.66 Million |
R$369.83 Million ≈ $72.57 Million |
-10.23pp |
| 2020-12-31 | 24.93% | R$108.43 Million ≈ $21.28 Million |
R$434.97 Million ≈ $85.35 Million |
-1.88pp |
| 2019-12-31 | 26.80% | R$104.21 Million ≈ $20.45 Million |
R$388.77 Million ≈ $76.28 Million |
+2.25pp |
| 2018-12-31 | 24.55% | R$75.06 Million ≈ $14.73 Million |
R$305.68 Million ≈ $59.98 Million |
+11.50pp |
| 2017-12-31 | 13.06% | R$34.26 Million ≈ $6.72 Million |
R$262.39 Million ≈ $51.49 Million |
-3.19pp |
| 2016-12-31 | 16.25% | R$38.57 Million ≈ $7.57 Million |
R$237.38 Million ≈ $46.58 Million |
-22.95pp |
| 2015-12-31 | 39.20% | R$90.03 Million ≈ $17.67 Million |
R$229.67 Million ≈ $45.07 Million |
-17.51pp |
| 2014-12-31 | 56.71% | R$101.83 Million ≈ $19.98 Million |
R$179.56 Million ≈ $35.23 Million |
+4.71pp |
| 2013-12-31 | 52.00% | R$71.80 Million ≈ $14.09 Million |
R$138.08 Million ≈ $27.09 Million |
-- |
About Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more